Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | MAOB | P27338 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 7/20 | 0.57 |
| ▸ | MIF | P14174 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | GAPDH | P04406 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28664040 | 0.88 | MAOB (0.66) | RAB9AKDM4EMAOBALDH1A1NPC1 | |
| SCHEMBL3398092 | 0.84 | GPR35 (0.48) | RAB9AKDM4EMAOBALDH1A1NPC1 | |
| SCHEMBL23212283 | 0.81 | RAB9A (0.75) | RAB9AKDM4EMAOBALDH1A1NPC1 | |
| SCHEMBL3131797 | 0.80 | RAB9A (0.69) | RAB9AKDM4EMAOBALDH1A1NPC1 | |
| SCHEMBL177366 | 0.80 | RAB9A (1.00) | RAB9AKDM4EMAOBALDH1A1NPC1 | |
| SCHEMBL30356319 | 0.80 | RAB9A (1.00) | RAB9AKDM4EMAOBALDH1A1NPC1 | |
| SCHEMBL6931520 | 0.77 | MAPT (0.72) | RAB9AKDM4EMAOBALDH1A1NPC1 | |
| SCHEMBL11492182 | 0.77 | MAOB (0.49) | RAB9AKDM4EMAOBALDH1A1NPC1 | |
| SCHEMBL6928495 | 0.77 | MAOB (0.68) | KDM4EMAOBALDH1A1MIFKMT2A | |
| SCHEMBL3400256 | 0.76 | GAPDH (0.55) | RAB9AKDM4EMAOBALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5371074-A | Use of saccharin derivatives as proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-06 | — | — | US | claimed |
| EP-0542372-A1 | 2-Substituted saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | claimed |
| CN-107709519-B | Method for stabilizing liquid-crystalline media | 默克专利股份有限公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-104793383-B | Liquid crystal display device with a light guide plate | 默克专利股份有限公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-2121678-B1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-11-03 | — | — | EP | disclosed |
| US-20090312364-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-12-17 | — | — | US | disclosed |
| EP-2121678-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074798-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2008-06-26 | — | — | WO | disclosed |
| US-5773456-A | EMPHYSEMA, RHEUMATOID ARTHRITIS AND PANCREATITIS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5578623-A | DRUGS FOR TREATMENT OF ARTHRITIS, PANCREATITIS, CYSTIC FIBROSIS, BRONCHITIS, RESPIRATORY DISORDERS | STERLING WINTHROP INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5464852-A | Used in treatment of degenerative diseases | STERLING WINTHROP INC. (US) | 1995-11-07 | — | — | US | disclosed |
| US-5380737-A | Enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0542371-A1 | Saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312364-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC6A2, SLC18A2, SLC18A1 | RAB9A 1674/4885KDM4E 1135/4885MAOB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.